All In Biotech

Drug Trial Radar · NCT02201004

TOFO Insulin Combination Trial

A Randomized, Double Blind Placebo Controlled 2-Arm Parallel Group, Multicenter Study With A 16-Week Treatment Assessing The Efficacy And Safety, And 52-Week Long Term Safety Including 36-Week Open Label Extension Of Tofogliflozin With Insulin Treatment In Type 2 Diabetes Mellitus

Last checked: Nov 19, 2026Latest source record: Oct 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 211 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

211

Actual

Start

Jun 2014

Primary completion

Jan 2016

Study completion Oct 2016

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Kowa Company, Ltd.
First posted
Jul 25, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 20 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: To assess the effects of tofogliflozin on glycemic control in comparison to placebo as an add-on treatment to insulin treatment in terms of glycated hemoglobin (HbA1c) reduction over a period of 16 weeks in patients with type 2 diabetes mellitus. To assess the safety of tofogliflozin in combination with insulin treatment throughout 52 weeks. Secondary Objectives: To assess the effects of tofogliflozin in comparison to placebo on: * Body weight * Fasting plasma glucose (FPG) * Postprandial plasma glucose (PPG) To assess the long term safety and tolerability of tofogliflozin.

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • TOFOGLIFLOZIN CSG452Drug

    Pharmaceutical form:tablet Route of administration: oral

  • insulinDrug

    Pharmaceutical form:solution Route of administration: subcutaneous

  • placeboDrug

    Pharmaceutical form:tablet Route of administration: oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in HbA1c from baselineTime frame: 16 weeks after first intake of investigational product

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number 392-028

    Adachi-ku, Japan

  • Investigational Site Number 392-007

    Atsugi-shi, Japan

  • Investigational Site Number 392-026

    Chuoh-ku, Japan

  • Investigational Site Number 392-021

    Fukuoka, Japan

  • Investigational Site Number 392-002

    Ichihara-shi, Japan

  • Investigational Site Number 392-012

    Iruma-shi, Japan

  • Investigational Site Number 392-003

    Kawaguchi-shi, Japan

  • Investigational Site Number 392-014

    Kitakyusyu-shi, Japan

  • Investigational Site Number 392-027

    Kobe, Japan

  • Investigational Site Number 392-004

    Koga-shi, Japan

  • Investigational Site Number 392-022

    Kunitachi-shi, Japan

  • Investigational Site Number 392-019

    Kurume-shi, Japan

  • Investigational Site Number 392-001

    Kyoto, Japan

  • Investigational Site Number 392-024

    Kyoto, Japan

  • Investigational Site Number 392-006

    Matsudo-shi, Japan

  • Investigational Site Number 392-008

    Mito, Japan

  • Investigational Site Number 392-030

    Musashino-shi, Japan

  • Investigational Site Number 392-029

    Okayama, Japan

  • Investigational Site Number 392-017

    Ōtsu, Japan

  • Investigational Site Number 392-011

    Sagamihara-shi, Japan

  • Investigational Site Number 392-020

    Sakaishi, Japan

  • Investigational Site Number 392-010

    Sapporo, Japan

  • Investigational Site Number 392-016

    Sendai, Japan

  • Investigational Site Number 392-018

    Shinjuku-ku, Japan

  • Investigational Site Number 392-005

    Shizuoka, Japan

  • Investigational Site Number 392-031

    Suita-shi, Japan

  • Investigational Site Number 392-015

    Sumida-ku, Japan

  • Investigational Site Number 392-023

    Sunto-gun, Japan

  • Investigational Site Number 392-013

    Tokorozawa-shi, Japan

  • Investigational Site Number 392-025

    Yokohama, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.